Tokyo Tape
Sign in
← Sapporo Clinical Laboratory

Half-year report · Q2

9776.TEDINET S100ULLX
Period2024-04-01 → 2024-09-30
Filed2024-11-11
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 44
MetricValuePeriodScopeSource row
Revenue¥10.0bn2024-04-01 → 2024-09-30Cons.Net sales
Revenue¥19.7bn2023-04-01 → 2024-03-31Cons.Net sales (5-year summary)
Revenue¥9.9bn2023-04-01 → 2023-09-30Cons.Net sales
Operating income¥338m2024-04-01 → 2024-09-30Cons.Operating income
Operating income¥291m2023-04-01 → 2023-09-30Cons.Operating income
Ordinary income¥343m2024-04-01 → 2024-09-30Cons.Ordinary income
Ordinary income¥515m2023-04-01 → 2024-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income¥296m2023-04-01 → 2023-09-30Cons.Ordinary income
Profit before tax¥344m2024-04-01 → 2024-09-30Cons.Income before income taxes
Profit before tax¥386m2023-04-01 → 2023-09-30Cons.Income before income taxes
Net income (owners)¥222m2024-04-01 → 2024-09-30Cons.Profit loss attributable to owners of parent
Net income (owners)¥380m2023-04-01 → 2024-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥226m2023-04-01 → 2023-09-30Cons.Profit loss attributable to owners of parent
Net income¥226m2024-04-01 → 2024-09-30Cons.Profit loss
Net income¥226m2023-04-01 → 2023-09-30Cons.Profit loss
Total assets¥16.4bnat 2024-09-30Cons.Assets
Total assets¥16.7bnat 2024-03-31Cons.Assets
Total assets¥16.7bnat 2023-09-30Cons.Total assets (5-year summary)
Total liabilities¥5.3bnat 2024-09-30Cons.Liabilities
Total liabilities¥5.5bnat 2024-03-31Cons.Liabilities
Net assets / equity¥11.1bnat 2024-09-30Cons.Net assets
Net assets / equity¥11.2bnat 2024-03-31Cons.Net assets
Net assets / equity¥11.0bnat 2023-09-30Cons.Net assets (5-year summary)
Cash and deposits¥3.4bnat 2024-09-30Cons.Cash and deposits
Cash and deposits¥4.0bnat 2024-03-31Cons.Cash and deposits
Cash & equivalents¥3.4bnat 2024-09-30Cons.Cash and cash equivalents
Cash & equivalents¥4.0bnat 2024-03-31Cons.Cash and cash equivalents
Cash & equivalents¥4.1bnat 2023-09-30Cons.Cash and cash equivalents
Cash & equivalents¥3.7bnat 2023-03-31dCons.Cash and cash equivalents
Operating cash flow¥407m2024-04-01 → 2024-09-30Cons.Net cash provided by used in operating activities
Operating cash flow¥1.1bn2023-04-01 → 2024-03-31Cons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow¥810m2023-04-01 → 2023-09-30Cons.Net cash provided by used in operating activities
Investing cash flow−¥584m2024-04-01 → 2024-09-30Cons.Net cash provided by used in investment activities
Investing cash flow−¥395m2023-04-01 → 2024-03-31Cons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow−¥171m2023-04-01 → 2023-09-30Cons.Net cash provided by used in investment activities
Financing cash flow−¥398m2024-04-01 → 2024-09-30Cons.Net cash provided by used in financing activities
Financing cash flow−¥370m2023-04-01 → 2024-03-31Cons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow−¥238m2023-04-01 → 2023-09-30Cons.Net cash provided by used in financing activities
EPS (basic)¥70.872024-04-01 → 2024-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥114.142023-04-01 → 2024-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥67.942023-04-01 → 2023-09-30Cons.Basic earnings loss per share (5-year summary)
Equity ratio66.3%at 2024-09-30Cons.Equity to asset ratio (5-year summary)
Equity ratio65.6%at 2024-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio64.4%at 2023-09-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 44
SegmentItemPeriodValue
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2024-04-01 → 2024-09-30¥58m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2024-04-01 → 2024-09-30¥54m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2024-04-01 → 2024-09-30¥4m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2024-04-01 → 2024-09-30¥37m
jpcrp040300-q2r_E04950-000Clinical Testing Businessreportable segmentrevenue2024-04-01 → 2024-09-30¥3.9bn
jpcrp040300-q2r_E04950-000Clinical Testing Businessreportable segmentrevenue external2024-04-01 → 2024-09-30¥3.9bn
jpcrp040300-q2r_E04950-000Clinical Testing Businessreportable segmentsegment profit2024-04-01 → 2024-09-30¥158m
jpcrp040300-q2r_E04950-000Dispensing Pharmacy Businessreportable segmentrevenue2024-04-01 → 2024-09-30¥5.6bn
jpcrp040300-q2r_E04950-000Dispensing Pharmacy Businessreportable segmentrevenue external2024-04-01 → 2024-09-30¥5.6bn
jpcrp040300-q2r_E04950-000Dispensing Pharmacy Businessreportable segmentsegment profit2024-04-01 → 2024-09-30¥352m
jpcrp040300-q2r_E04950-000Medical Devices And Maintenance Businessreportable segmentrevenue2024-04-01 → 2024-09-30¥800m
jpcrp040300-q2r_E04950-000Medical Devices And Maintenance Businessreportable segmentrevenue external2024-04-01 → 2024-09-30¥426m
jpcrp040300-q2r_E04950-000Medical Devices And Maintenance Businessreportable segmentrevenue intersegment2024-04-01 → 2024-09-30¥375m
jpcrp040300-q2r_E04950-000Medical Devices And Maintenance Businessreportable segmentsegment profit2024-04-01 → 2024-09-30−¥2m
—segment totalrevenue2024-04-01 → 2024-09-30¥10.3bn
—segment totalrevenue external2024-04-01 → 2024-09-30¥9.9bn
—segment totalrevenue intersegment2024-04-01 → 2024-09-30¥375m
—segment totalsegment profit2024-04-01 → 2024-09-30¥507m
Total Of Reportable Segments And Otherssegment totalrevenue2024-04-01 → 2024-09-30¥10.4bn
Total Of Reportable Segments And Otherssegment totalrevenue external2024-04-01 → 2024-09-30¥10.0bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2024-04-01 → 2024-09-30¥379m
Total Of Reportable Segments And Otherssegment totalsegment profit2024-04-01 → 2024-09-30¥545m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2023-04-01 → 2023-09-30¥58m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2023-04-01 → 2023-09-30¥56m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2023-04-01 → 2023-09-30¥2m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2023-04-01 → 2023-09-30¥41m
jpcrp040300-q2r_E04950-000Clinical Testing Businessreportable segmentrevenue2023-04-01 → 2023-09-30¥3.8bn
jpcrp040300-q2r_E04950-000Clinical Testing Businessreportable segmentrevenue external2023-04-01 → 2023-09-30¥3.8bn
jpcrp040300-q2r_E04950-000Clinical Testing Businessreportable segmentsegment profit2023-04-01 → 2023-09-30¥78m
jpcrp040300-q2r_E04950-000Dispensing Pharmacy Businessreportable segmentrevenue2023-04-01 → 2023-09-30¥5.5bn
jpcrp040300-q2r_E04950-000Dispensing Pharmacy Businessreportable segmentrevenue external2023-04-01 → 2023-09-30¥5.5bn
jpcrp040300-q2r_E04950-000Dispensing Pharmacy Businessreportable segmentsegment profit2023-04-01 → 2023-09-30¥377m
jpcrp040300-q2r_E04950-000Medical Devices And Maintenance Businessreportable segmentrevenue2023-04-01 → 2023-09-30¥798m
jpcrp040300-q2r_E04950-000Medical Devices And Maintenance Businessreportable segmentrevenue external2023-04-01 → 2023-09-30¥492m
jpcrp040300-q2r_E04950-000Medical Devices And Maintenance Businessreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥306m
jpcrp040300-q2r_E04950-000Medical Devices And Maintenance Businessreportable segmentsegment profit2023-04-01 → 2023-09-30−¥7m
—segment totalrevenue2023-04-01 → 2023-09-30¥10.1bn
—segment totalrevenue external2023-04-01 → 2023-09-30¥9.8bn
—segment totalrevenue intersegment2023-04-01 → 2023-09-30¥306m
—segment totalsegment profit2023-04-01 → 2023-09-30¥448m
Total Of Reportable Segments And Otherssegment totalrevenue2023-04-01 → 2023-09-30¥10.2bn
Total Of Reportable Segments And Otherssegment totalrevenue external2023-04-01 → 2023-09-30¥9.9bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2023-04-01 → 2023-09-30¥308m
Total Of Reportable Segments And Otherssegment totalsegment profit2023-04-01 → 2023-09-30¥489m

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 543
ItemContextValueUnit
Shareholders equityPrior1YearInstant10848906000JPY
Shareholders equityCurrentQuarterInstant10804737000JPY
Valuation difference on available for sale securitiesPrior1YearInstant87746000JPY
Valuation difference on available for sale securitiesCurrentQuarterInstant71583000JPY
Valuation and translation adjustmentsPrior1YearInstant87746000JPY
Valuation and translation adjustmentsCurrentQuarterInstant71583000JPY
Non controlling interestsPrior1YearInstant246386000JPY
Non controlling interestsCurrentQuarterInstant249889000JPY
Net assetsPrior1YearInstant11183039000JPY
Net assetsCurrentQuarterInstant11126209000JPY
Liabilities and net assetsPrior1YearInstant16680947000JPY
Liabilities and net assetsCurrentQuarterInstant16408708000JPY
Net salesPrior1YTDDuration9862397000JPY
Net salesCurrentYTDDuration9996976000JPY
Cost of salesPrior1YTDDuration6906947000JPY
Cost of salesCurrentYTDDuration6963100000JPY
Gross profitPrior1YTDDuration2955450000JPY
Gross profitCurrentYTDDuration3033876000JPY
Selling general and administrative expensesPrior1YTDDuration2664149000JPY
Selling general and administrative expensesCurrentYTDDuration2695992000JPY
Operating incomePrior1YTDDuration291301000JPY
Operating incomeCurrentYTDDuration337884000JPY
Interest income noiPrior1YTDDuration86000JPY
Interest income noiCurrentYTDDuration36000JPY
Dividends income noiPrior1YTDDuration2804000JPY
Dividends income noiCurrentYTDDuration2805000JPY
Rent income noiPrior1YTDDuration20027000JPY
Rent income noiCurrentYTDDuration25890000JPY
Subsidy income noi bountyPrior1YTDDuration13704000JPY
Subsidy income noi bountyCurrentYTDDuration264000JPY
Other noiPrior1YTDDuration5079000JPY
Other noiCurrentYTDDuration2258000JPY
Non operating incomePrior1YTDDuration41702000JPY
Non operating incomeCurrentYTDDuration31254000JPY
Interest expenses noePrior1YTDDuration3700000JPY
Interest expenses noeCurrentYTDDuration3430000JPY
Cost of lease revenue noePrior1YTDDuration20000000JPY
Cost of lease revenue noeCurrentYTDDuration21711000JPY
Subsidy refund amount noePrior1YTDDuration8394000JPY
Subsidy refund amount noeCurrentYTDDuration－JPY
Other noePrior1YTDDuration4559000JPY
Other noeCurrentYTDDuration947000JPY
Non operating expensesPrior1YTDDuration36654000JPY
Non operating expensesCurrentYTDDuration26089000JPY
Ordinary incomePrior1YTDDuration296350000JPY
Ordinary incomeCurrentYTDDuration343050000JPY
Gain on sales of noncurrent assets eiPrior1YTDDuration－JPY
Gain on sales of noncurrent assets eiCurrentYTDDuration1157000JPY
Penalty income eiPrior1YTDDuration138050000JPY
Penalty income eiCurrentYTDDuration－JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 14 of 14 passed
balance sheet identityconsolidated 2024-03-31pass rounding
balance sheet identityconsolidated 2024-09-30pass rounding
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2024-03-31pass
statement vs summary · net assetsconsolidated 2024-09-30pass
statement vs summary · net income attributable to parentconsolidated 2023-04-01/2023-09-30pass
statement vs summary · net income attributable to parentconsolidated 2024-04-01/2024-09-30pass
statement vs summary · operating cash flowconsolidated 2023-04-01/2023-09-30pass
statement vs summary · operating cash flowconsolidated 2024-04-01/2024-09-30pass
statement vs summary · revenueconsolidated 2023-04-01/2023-09-30pass
statement vs summary · revenueconsolidated 2024-04-01/2024-09-30pass
statement vs summary · total assetsconsolidated 2024-03-31pass
statement vs summary · total assetsconsolidated 2024-09-30pass